跳至主要内容
临床试验/CTIS2024-513665-40-00
CTIS2024-513665-40-00进行中(未招募)1 期

Randomized, open-label, single dose, two-period, two-treatment, cross-over bioequivalence study comparing test product Rivaroxaban/Acetylsalicylic acid, tablet, 2.5 mg/50 mg (given as two tablets) to reference product Xarelto 2.5 mg film-coated tablets (given as two tablets) and Aspirin® N 100 mg tablet in healthy male and female subjects under fasting conditions.

Adamed Pharma S.A.0 个研究点目标入组 62 人开始时间: 2024年5月9日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
62

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 64(—)
性别
All

入选标准

  • 未提供

排除标准

  • 未提供

研究者

相似试验

Unknown
1 期
Open-label, randomized, single dose, two-period, two-treatment cross-over bioequivalence study of Dienogest 2 mg tablets from Naari Pharma Pvt. Ltd. - India vs Visanne 2 mg tablets, from Bayer Weimar GmbH UND Co.KG, Weimar, Germany in healthy female subjects under fasting conditionsHealthy subjectsBioequivalenceDienogest 2 mg
TCTR20220906003Abbott Laboratories Limited, Thailand44
进行中(未招募)
1 期
Randomized, open-label, single dose, two-period, cross-over bioequivalence study comparing test formulation Rosuvastatin/Amlodipine/Ramipril capsule, hard 10mg/5mg/5mg versus reference products Crestor 10 mg film coated tablets, Norvasc 5 mg tablets, Tritace 5 mg tablets in healthy male and female subjects under fasting conditions.
CTIS2023-503822-38-00Adamed Pharma S.A.60
尚未招募
1 期
A Single Dose, Randomized, Open-label, Two-period, Two-sequence Crossover Bioequivalence Study of Generic Linagliptin/Metformin Hydrochloride Tablets 2.5 mg/1000 mg and Reference Product (TRAJENTA DUO) in Healthy Thai Volunteers under Fed ConditionsBioequivalence Study Healthy Thai Volunteers
TCTR20231012008International Bio Service Co., Ltd.40
进行中(未招募)
1 期
Clinical trial in Healthy Volunteers to test Valsartan PharmacokineticsHypertension
EUCTR2016-004323-23-Outside-EU/EEAovartis86
已完成
1 期
A study to compare the concentrations of valsartan in plasma when valsartan is taken as solution formulation and as tablet formulation.
CTRI/2010/091/001094ovartis Healthcare Private Limited Andhra Pradesh India30